• 
    
    <tbody id="a2zym"></tbody>
    1. <progress id="a2zym"></progress>
      <th id="a2zym"><track id="a2zym"><dl id="a2zym"></dl></track></th>
      <legend id="a2zym"><p id="a2zym"></p></legend>
      <rp id="a2zym"></rp>
      <tbody id="a2zym"></tbody>
      <button id="a2zym"></button>
      <dd id="a2zym"><pre id="a2zym"><dl id="a2zym"></dl></pre></dd><button id="a2zym"><object id="a2zym"><menuitem id="a2zym"></menuitem></object></button>
      <tbody id="a2zym"></tbody>

      <th id="a2zym"><track id="a2zym"></track></th>

      <span id="a2zym"></span>

    2. <rp id="a2zym"></rp>

      AACR 2024 Poster Resources

      April 10, 2024
      Preclinical PD-1 Resistance Models: Crucial Tools for Unveiling PD-1 Resistance Mechanisms and Advancing Novel Treatment Strategies

      Preclinical PD-1 Resistance Models: Crucial Tools for Unveiling PD-1 Resistance Mechanisms and Advancing Novel Treatment Strategies

      The interaction between PD-1 and PD-L1 promotes tumor immune evasion, but immune checkpoint inhibitors can reinvigorate the immune system. However, most patients don't respond well to anti-PD-1/PD-L1 therapy, leading to acquired resistance. Establishing reliable preclinical resistance models is vital for understanding resistance mechanisms and developing new treatments.
      Download
      NeoMab?: A Novel Platform for Fully Human Therapeutic Antibody Development

      NeoMab?: A Novel Platform for Fully Human Therapeutic Antibody Development

      Antibodies and related therapies have shown promise in treating human diseases, but challenges like immunogenicity and limited preclinical models hinder drug development. GemPharmatech's NeoMab? mouse model addresses these issues by producing fully human antibodies, offering robust immune responses and high-affinity antibodies against various antigens. Utilizing human genes, NeoMab? accelerates the discovery of human antibody drugs, potentially surpassing FDA-approved treatments.
      Download
      Patient-derived xenograft (PDX) models with differential HER2 expression for preclinical evaluation of HER2-targeted therapies

      Patient-derived xenograft (PDX) models with differential HER2 expression for preclinical evaluation of HER2-targeted therapies

      HER2 overexpression is common in gastric and gastroesophageal cancer, emphasizing the need to target HER2 in treatment. Gempharmatech offers PDX gastric cancer models with varying HER2 levels, identified through immunohistochemistry. These models, exemplified by one with heterogeneous HER2 expression, provide detailed insights into drug responses, particularly highlighting the efficacy of Trastuzumab deruxtecan, contributing to precision medicine in HER2-targeted therapy development.
      Download
      Development of a Novel Murine Model, NCG-M/hIL15, for Enhanced Post-HSC Transplantation Immunoreconstruction

      Development of a Novel Murine Model, NCG-M/hIL15, for Enhanced Post-HSC Transplantation Immunoreconstruction

      The NCG-M/hIL15 model represents a significant advancement in preclinical research by addressing limitations in existing murine models related to human immune responses, particularly in natural killer (NK) cell and myeloid lineage cell reconstitution post-HSC transplantation. This model demonstrates improved reconstitution of NK cells, T cells, and myeloid lineage cells compared to conventional models, enhancing the simulation of human immune responses and offering potential benefits for studying immunology and developing novel therapies.
      Download
      Development and Application of the NCG-hIL2 Mouse Model: A Humanized Platform for Enhanced NK Cell Evaluation in ADCC Efficacy Testing

      Development and Application of the NCG-hIL2 Mouse Model: A Humanized Platform for Enhanced NK Cell Evaluation in ADCC Efficacy Testing

      The NCG-hIL2 mouse model, engineered to express human Interleukin-2 (IL2), facilitates the reconstitution of human NK cells, aiding in the assessment of therapeutic antibodies' efficacy, notably in ADCC. This model enhances our understanding of NK cell development and serves as a valuable tool for studying immunotherapies, particularly in cancer treatment.
      Download
      BALB/c-hIL12RB1/hIL12RB2: A Robust Model for Preclinical Research in Human IL-12 Therapy

      BALB/c-hIL12RB1/hIL12RB2: A Robust Model for Preclinical Research in Human IL-12 Therapy

      Recent interest in Interleukin-12 (IL-12) as a therapeutic target led to the development of the BALB/c-hIL12RB1/hIL12RB2 humanized mouse model, preserving intracellular signaling and effectively expressing human IL12RB1 and IL12RB2. This model demonstrates enhanced activation of cytotoxic lymphocytes, natural killer cells, and interferon production, validating IL-12 as a potential anti-tumor drug target. Successful validation of the model suggests its utility in understanding IL-12's therapeutic mechanisms and developing novel anti-tumor treatments.
      Download
      Breaking Through ADCs Resistance: Constructing Preclinical Enhertu-induced Resistant Model

      Breaking Through ADCs Resistance: Constructing Preclinical Enhertu-induced Resistant Model

      Antibody-drug conjugates (ADCs) have shown significant efficacy in HER2-positive breast cancer, but the emergence of resistance underscores the need to understand resistance mechanisms. Preclinical models, like the Enhertu-resistant tumor model developed from continuous Enhertu treatment in JIMT-1 tumor tissues in mice, offer insights into resistance mechanisms involving various cellular components within the tumor microenvironment. These models serve as valuable tools for predicting and understanding ADC resistance, aiding in the development of strategies to overcome resistance in clinical settings.
      Download
      架空历史小说 天地之间小说